Scaling up for unprecedented global vaccine manufacturing
Vaxxas announces Merck (known as MSD outside the US and Canada) milestone and Harro Höfliger manufacturing alliance.
Vaxxas has announced two developments relating to its novel high-density microarray patch (HD-MAP), which uses an ultra-high density array of projections — invisible to the naked human eye — applied to the skin to rapidly deliver any vaccine to the abundant immune cells immediately below the skin surface.
Vaxxas HD-MAP could be a game-changing technology for vaccine delivery in pandemic situations such as COVID-19 or influenza because it makes it possible to vaccinate up to six times more people using the same amount of vaccine — each patch uses a percentage of the vaccine dose needed by conventional delivery approaches.
Merck has exercised its option to utilize Vaxxas’ proprietary HD-MAP) platform for an unidentified vaccine candidate. The company also retains an option to license the HD-MAP technology for two additional vaccines.
Vaxxas will receive $12 million (A$18 million) in a combination of equity funding and option fees associated with the agreement. In addition, the company is eligible to receive future option, development, and commercial milestone payments.
In a separate agreement, Vaxxas and Harro Höfliger, a leader in sterile processing and scale-up of new pharmaceutical products, technologies and devices, will develop the world’s first high-throughput aseptic line for vaccine-HD-MAP production.
Single, aseptic-based lines will have a targeted throughput of up to 5 million vaccine products/week. Initial efforts are focused on a pilot line operating in 2021 to be used to support late-stage clinical studies.
"A major challenge in commercializing microarray patches — like Vaxxas’ HD-MAP — for vaccination is the ability to manufacture at industrially relevant scale while meeting stringent sterility and quality standards. Our novel device design along with our innovative vaccine coating and quality verification technologies are an excellent fit for integration with Harro Höfliger’s aseptic process automation platforms. Adopting a modular approach, it will be possible to achieve an output of tens-of-millions of vaccine-HD-MAP products per week,” said David L. Hoey, President and CEO of Vaxxas.
For routine infectious disease more than 750 million vaccinations are administered worldwide each year by needle/syringe. In the case of pandemic response, billions of vaccinations may need to occur in a variety of settings. Vaxxas’ HD-MAP has the potential to create new needle-free vaccine products with enhanced immune response and designed for improved safety, storage, and distribution logistics to extend the reach of vaccines and improve vaccination efficiency and effectiveness.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance